RBM as Competitive Advantage for Mid-sized CROs

WhitePaper RBM for Mid-sized CROs

Recent research shows, the size of sponsors correlates with the size of service providers. Big Pharma relies on the large, full-service CROs if they are running a large clinical trial.

As the outsourcing world has always moved in cycles, today, there is a chance to change the situation. Mid-sized CROs can demonstrate to sponsors their experience and provide an evidence-based proof of expertise, needed to win a bigger project, e.g., multinational phase III trial.

Embracing RBM, a company’s smaller size can become an advantage.

Read more and download the White Paper

Download White Paper
By | 2016-11-16T18:35:46+00:00 April 27, 2015|White Paper|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Upcoming Events

  1. SCDM 2018 ANNUAL CONFERENCE – Seattle

    September 23 - September 26
  2. PCT Europe 2018

    November 28 - November 29

Register Today!

Get Free Test Access